Cardinal Health 2011 Annual Report Download - page 95

Fisca
l
2010
D
uring fiscal 2010, we repurchased 7.4 million Common Shares having an aggregate cost of approximatel
y
$
250.0 million, of which
$
19.8 million cash settled in fiscal 2011. The average price paid per common share for
a
ll Common Shares repurchased durin
g
fiscal 2010 was $33.85.
Fisca
l
200
9
We did not repurchase any Common Shares during fiscal 2009.
1
5. EARNING
S
PER
S
HARE
B
as
i
c EPS
i
s compute
db
y
di
v
idi
ng net earn
i
ngs (t
h
e numerator)
b
yt
h
ewe
i
g
h
te
d
average num
b
er o
f
C
ommon Shares outstandin
g
durin
g
each period (the denominator). Diluted EPS is similar to the computation fo
r
B
asic EPS, except that the denominator is increased by the dilutive effect of vested and unvested stock options,
restr
i
cte
d
s
h
ares an
d
restr
i
cte
d
s
h
are un
i
ts compute
d
us
i
ng t
h
e treasury stoc
k
met
h
o
d
.T
h
e tota
l
num
b
er o
f
C
ommon Shares issued, less the Common Shares held in treasur
y
, is used to determine the Common Share
s
o
utstanding
.
T
he followin
g
table reconciles the number of Common Shares used to compute Basic EPS and Diluted EPS
f
or fiscal 2011, 2010 and 2009:
Fiscal Year Ended June 30,
(
in millions
)
2
0
1
1
2
0
1
0
2009
We
i
g
h
te
d
-average Common S
h
ares–
b
as
i
c
.................................
3
4
8
.
6 358
.
835
7.
6
Effect of dilutive securities:
Employee stock options, restricted shares and restricted share unit
s
.
........ 3.9 2.6 3.
9
Wei
g
hted-avera
g
e Common Shares–diluted
................................
35
2.
5
361.4 361.
5
Th
e
f
o
ll
ow
i
ng ta
bl
e presents t
h
e num
b
er o
f
potent
i
a
ll
y
dil
ut
i
ve secur
i
t
i
es t
h
at were ant
i
-
dil
ut
i
ve
f
or
fi
sca
l
2011
,
2010 an
d
2009
:
F
i
scal Year Ended June 30,
(
in millions)
2011
2010
2009
Anti-dilutive securitie
s
................................................
1
1.4 19.0 28.8
1
6.
S
E
G
MENT INF
O
RMATI
O
N
O
ur operations are principall
y
mana
g
ed on a products and services basis and are comprised of two
reporta
bl
e segments: P
h
armaceut
i
ca
l
an
d
Me
di
ca
l
.T
h
e
f
actors
f
or
d
eterm
i
n
i
ng t
h
e reporta
bl
e segments
i
nc
l
u
de
t
h
e manner
i
nw
hi
c
h
mana
g
ement eva
l
uates our per
f
ormance com
bi
ne
d
w
i
t
h
t
h
e nature o
f
t
h
e
i
n
di
v
id
ua
lb
us
i
nes
s
a
ctivities. The results of the acquisitions of Kinra
y
, Yon
g
Yu and P4 Healthcare are included within our
P
h
armaceut
i
ca
l
segment
f
rom t
h
e
d
ate o
f
acqu
i
s
i
t
i
on. See Note 2
f
or a
d
escr
i
pt
i
on o
f
t
h
ese acqu
i
s
i
t
i
ons.
T
he Pharmaceutical se
g
ment distributes branded and
g
eneric pharmaceutical, over-the-counter healthcare
a
n
d
consumer pro
d
ucts. It a
l
so operates nuc
l
ear p
h
armac
i
es an
d
cyc
l
otron
f
ac
ili
t
i
es t
h
at prepare an
dd
e
li
ve
r
ra
di
op
h
armaceut
i
ca
l
s
f
or use
i
n nuc
l
ear
i
ma
gi
n
g
an
d
ot
h
er proce
d
ures
i
n
h
osp
i
ta
l
san
d
c
li
n
i
cs. In a
ddi
t
i
on, t
hi
s
se
g
ment provides third-part
y
lo
g
istics support services to hospitals, clinics, and other providers; franchises retai
l
p
h
armac
i
es un
d
er t
h
eMe
di
c
i
ne S
h
opp
e
®
a
n
d
Me
di
ca
p
®
b
ran
d
s; an
d
prov
id
es p
h
armacy serv
i
ces to
h
osp
i
ta
l
san
d
o
t
h
er
h
ea
l
t
h
care
f
ac
ili
t
i
es. T
hi
sse
g
ment a
l
so
di
str
ib
utes spec
i
a
l
t
y
p
h
armaceut
i
ca
l
pro
d
ucts an
d
prov
id
es serv
i
ce
s
to pharmaceutical manufacturers, third-part
y
pa
y
ors and healthcare service providers supportin
g
the marketin
g,
di
str
ib
ut
i
on an
d
payment
f
or spec
i
a
l
ty p
h
armaceut
i
ca
l
pro
d
ucts. T
hi
s segment a
l
so prov
id
es p
h
armaceut
i
ca
l
6
9